Targeting ion channels for the treatment of autoimmune neuroinflammation

Pharmacological targeting of ion channels has long been recognized as an attractive strategy for the treatment of various diseases. Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system with a prominent neurodegenerative component. A multitude of different cell types are in...

Full description

Bibliographic Details
Main Authors: Stefan Bittner, Sven G. Meuth
Format: Article
Language:English
Published: SAGE Publishing 2013-09-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/1756285613487782
id doaj-7f2218a068714c02b91ce59e84a42fff
record_format Article
spelling doaj-7f2218a068714c02b91ce59e84a42fff2020-11-25T03:49:57ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28561756-28642013-09-01610.1177/1756285613487782Targeting ion channels for the treatment of autoimmune neuroinflammationStefan BittnerSven G. MeuthPharmacological targeting of ion channels has long been recognized as an attractive strategy for the treatment of various diseases. Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system with a prominent neurodegenerative component. A multitude of different cell types are involved in the complex pathophysiology of this disorder, including cells of the immune system (e.g. T and B lymphocytes and microglia), the neurovascular unit (e.g. endothelial cells and astrocytes) and the central nervous system (e.g. astrocytes and neurons). The pleiotropic expression and function of ion channels gives rise to the attractive opportunity of targeting different players and pathophysiological aspects of MS by the modulation of ion channel function in a cell-type and context-specific manner. We discuss the emerging knowledge about ion channels in the context of autoimmune neuroinflammation. While some pharmacological targets are at the edge of clinical translation, others have only recently been discovered and are still under investigation. Special focus is given to those candidates that could be attractive novel targets for future therapeutic approaches in neuroimmune autoinflammation.https://doi.org/10.1177/1756285613487782
collection DOAJ
language English
format Article
sources DOAJ
author Stefan Bittner
Sven G. Meuth
spellingShingle Stefan Bittner
Sven G. Meuth
Targeting ion channels for the treatment of autoimmune neuroinflammation
Therapeutic Advances in Neurological Disorders
author_facet Stefan Bittner
Sven G. Meuth
author_sort Stefan Bittner
title Targeting ion channels for the treatment of autoimmune neuroinflammation
title_short Targeting ion channels for the treatment of autoimmune neuroinflammation
title_full Targeting ion channels for the treatment of autoimmune neuroinflammation
title_fullStr Targeting ion channels for the treatment of autoimmune neuroinflammation
title_full_unstemmed Targeting ion channels for the treatment of autoimmune neuroinflammation
title_sort targeting ion channels for the treatment of autoimmune neuroinflammation
publisher SAGE Publishing
series Therapeutic Advances in Neurological Disorders
issn 1756-2856
1756-2864
publishDate 2013-09-01
description Pharmacological targeting of ion channels has long been recognized as an attractive strategy for the treatment of various diseases. Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system with a prominent neurodegenerative component. A multitude of different cell types are involved in the complex pathophysiology of this disorder, including cells of the immune system (e.g. T and B lymphocytes and microglia), the neurovascular unit (e.g. endothelial cells and astrocytes) and the central nervous system (e.g. astrocytes and neurons). The pleiotropic expression and function of ion channels gives rise to the attractive opportunity of targeting different players and pathophysiological aspects of MS by the modulation of ion channel function in a cell-type and context-specific manner. We discuss the emerging knowledge about ion channels in the context of autoimmune neuroinflammation. While some pharmacological targets are at the edge of clinical translation, others have only recently been discovered and are still under investigation. Special focus is given to those candidates that could be attractive novel targets for future therapeutic approaches in neuroimmune autoinflammation.
url https://doi.org/10.1177/1756285613487782
work_keys_str_mv AT stefanbittner targetingionchannelsforthetreatmentofautoimmuneneuroinflammation
AT svengmeuth targetingionchannelsforthetreatmentofautoimmuneneuroinflammation
_version_ 1724492961977204736